Back to Search Start Over

Tarsus posts positive results on eyedrop treatment for eyelid mange, expects to file for FDA approval next year.

Authors :
LaHucik, Kyle
Source :
FierceBiotech; 6/21/2021, pN.PAG-N.PAG, 1p
Publication Year :
2021

Abstract

Tarsus Pharmaceuticals met all primary and secondary endpoints in a pivotal phase 2b/3 trial of its eyedrop treatment for eyelid mange, and expects to file for regulatory approval next year following results of another pivotal study already underway. [ABSTRACT FROM AUTHOR]

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
151047042